Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+T cells

Authors: Meriem Hasmim, Cécile Badoual, Philippe Vielh, Françoise Drusch, Virginie Marty, Agnès Laplanche, Mariana de Oliveira Diniz, Hélène Roussel, Eléonore De Guillebon, Stéphane Oudard, Stéphane Hans, Eric Tartour, Salem Chouaib

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Our group has previously shown that EPHRIN-A1 and SCINDERIN expression by tumor cells rendered them resistant to cytotoxic T lymphocyte-mediated lysis. Whereas the prognostic value of EPHRIN-A1 expression in cancer has already been studied, the role of SCINDERIN presence remains to be established. In the present work, we investigated the prognosis value of EPHRIN-A1 and SCINDERIN expression in head and neck carcinomas. In addition, we monitored the HLA-class I expression by tumor cells and the presence of tumor-infiltrating CD8+ T cells to evaluate a putative correlation between these factors and the survival prognosis by themselves or related to EPHRIN-A1 and SCINDERIN expression.

Methods

Tumor tissue sections of 83 patients with head and neck cancer were assessed by immunohistochemistry for the expression of EPHRIN-A1, SCINDERIN, HLA class I molecules and the presence of CD8+ T cells.

Results

No significant prognosis value could be attributed to these factors independently, despite a tendency of association between EPHRIN-A1 and a worse clinical outcome. No prognostic value could be observed when CD8+ T cell tumor infiltration was analyzed combined with EPHRIN-A1, SCINDERIN or HLA class I expression.

Conclusion

These results highlight that molecules involved in cancer cell resistance to cytotoxic T lymphocytes by themselves are not a sufficient criteria for prognosis determination in cancer patients. Other intrinsic or tumor microenvironmental features should be considered in prognostic evaluation.
Appendix
Available only for authorised users
Literature
1.
Mehanna H, Paleri V, West CM, Nutting C: Head and neck cancer–Part 1: Epidemiology, presentation, and prevention. Bmj. 2010, 341: c4684-10.1136/bmj.c4684.CrossRefPubMed
2.
Mehanna H, West CM, Nutting C, Paleri V: Head and neck cancer–Part 2: Treatment and prognostic factors. Bmj. 2010, 341: c4690-10.1136/bmj.c4690.CrossRefPubMed
3.
Badoual C, Bouchaud G, Agueznay Nel H, Mortier E, Hans S, Gey A, Fernani F, Peyrard S, Puig PL, Bruneval P, et al: The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res. 2008, 68 (10): 3907-3914. 10.1158/0008-5472.CAN-07-6842.CrossRefPubMed
4.
Tartour E, Mosseri V, Jouffroy T, Deneux L, Jaulerry C, Brunin F, Fridman WH, Rodriguez J: Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet. 2001, 357 (9264): 1263-1264. 10.1016/S0140-6736(00)04420-2.CrossRefPubMed
5.
Schmitz S, Machiels JP: Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications. Expert Rev Anticancer Ther. 2010, 10 (9): 1471-1484. 10.1586/era.10.115.CrossRefPubMed
6.
Brinkman BM, Wong DT: Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol. 2006, 18 (3): 228-233. 10.1097/01.cco.0000219250.15041.f8.CrossRefPubMed
7.
Mami-Chouaib F, Echchakir H, Dorothee G, Vergnon I, Chouaib S: Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev. 2002, 188: 114-121. 10.1034/j.1600-065X.2002.18810.x.CrossRefPubMed
8.
Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, et al: Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother. 2008, 31 (1): 101-112. 10.1097/CJI.0b013e318159f5ba.CrossRefPubMed
9.
Helmich BK: The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol. 2001, 166 (11): 6500-6508. 11):6500–6508CrossRefPubMed
10.
Blohm UPD, van der Kogel AJ, Pircher H: Solid tumors "melt" from the inside after successful CD8 T cell attac. Eur J Immunol. 2006, 36 (2): 468-477. 10.1002/eji.200526175.CrossRefPubMed
11.
Hollenbaugh JA: IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol. 2006, 177 (5): 3004-3011.CrossRefPubMed
12.
Dunn GPBA, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002, 3: 991-998. 10.1038/ni1102-991.CrossRefPubMed
13.
Dunn GPOL, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004, 21: 137-148. 10.1016/j.immuni.2004.07.017.CrossRefPubMed
14.
Fridman WHGJ, Pages F, Tartour E, Sautes-Fridman C, et al: Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011, 71: 5601-5605. 10.1158/0008-5472.CAN-11-1316.CrossRefPubMed
15.
Galon JCA, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139.CrossRefPubMed
16.
Budhu S, Loike JD, Pandolfi A, Han S, Catalano G, Constantinescu A, Clynes R, Silverstein SC: CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Clin Cancer Res. 2010, 207 (1): 223-235.
17.
Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G, et al: Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors. Sci Transl Med. 2013, 5 (172): 172-ra120CrossRef
18.
Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H: Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001, 61 (13): 5132-5136.PubMed
19.
Bromwich EJ, McArdle PA, Canna K, McMillan DC, McNicol AM, Brown M, Aitchison M: The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer. 2003, 89 (10): 1906-1908. 10.1038/sj.bjc.6601400.CrossRefPubMedPubMedCentral
20.
Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, van Heerde P, Baars JW, Kluin PM, Kluin-Nelemans JC, van Diest PJ, Middeldorp JM, et al: Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood. 1997, 89 (4): 1376-1382.PubMed
21.
Muris JJ, Meijer CJ, Cillessen SA, Vos W, Kummer JA, Bladergroen BA, Bogman MJ, MacKenzie MA, Jiwa NM, van Heukelom LH S, et al: Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia. 2004, 18 (3): 589-596. 10.1038/sj.leu.2403240.CrossRefPubMed
22.
Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, et al: Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006, 12 (2): 465-472. 10.1158/1078-0432.CCR-05-1886.CrossRefPubMed
23.
Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, Mami-Chouaib F, Chouaib S: Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 2012, 72 (18): 4629-4641. 10.1158/0008-5472.CAN-12-1383.CrossRefPubMed
24.
Hasmim M, Noman MZ, Lauriol J, Benlalam H, Mallavialle A, Rosselli F, Mami-Chouaib F, Alcaide-Loridan C, Chouaib S: Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells. J Immunol. 2011, 187 (8): 4031-4039. 10.4049/jimmunol.1101011.CrossRefPubMed
25.
Noman MZ, Buart S, Van Pelt J, Richon C, Hasmim M, Leleu N, Suchorska WM, Jalil A, Lecluse Y, El Hage F, et al: The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol. 2009, 182 (6): 3510-3521. 10.4049/jimmunol.0800854.CrossRefPubMed
26.
Abouzahr S, Bismuth G, Gaudin C, Caroll O, Van Endert P, Jalil A, Dausset J, Vergnon I, Richon C, Kauffmann A, et al: Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci U S A. 2006, 103 (5): 1428-1433. 10.1073/pnas.0510454103.CrossRefPubMedPubMedCentral
27.
Hamai A, Meslin F, Benlalam H, Jalil A, Mehrpour M, Faure F, Lecluse Y, Vielh P, Avril MF, Robert C, et al: ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res. 2008, 68 (23): 9854-9864. 10.1158/0008-5472.CAN-08-0719.CrossRefPubMed
28.
Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, Buart S, Berchem G, Romero P, Mami-Chouaib F, et al: Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res. 2011, 71 (18): 5976-5986. 10.1158/0008-5472.CAN-11-1094.CrossRefPubMed
29.
Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J: PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009, 21 (9): 1065-1077. 10.1093/intimm/dxp072.CrossRefPubMedPubMedCentral
30.
Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, et al: PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013, 73 (1): 128-138. 10.1158/0008-5472.CAN-12-2606.CrossRefPubMed
31.
Pasquale EB: Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008, 133 (1): 38-52. 10.1016/j.cell.2008.03.011.CrossRefPubMed
32.
Iida HHM, Kawai HF, Yamashita T, Shirota Y, Wang BC, Miao H, Kaneko S: Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut. 2005, 54 (6): 843-851. 10.1136/gut.2004.049486.CrossRefPubMedPubMedCentral
33.
Xu FZW, Li J, Shanshen Z, Cui J, Nesland JM, Suo Z: Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res. 2005, 25 (4): 2943-2950.PubMed
34.
Shao ZZF, Song K, Zhang H, Liu K, Shang Z: EphA2/ephrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland. J Oral Maxillofac Surg. 2013, 71 (5): 869-878. 10.1016/j.joms.2012.10.026.CrossRefPubMed
35.
Miao HLD, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, Sloan AE, Cohen ML, Wang B: EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell. 2009, 16 (1): 9-20. 10.1016/j.ccr.2009.04.009.CrossRefPubMedPubMedCentral
36.
Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, Mittal SK: Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther. 2004, 11 (11): 757-766. 10.1038/sj.cgt.7700761.CrossRefPubMed
37.
Noren NK, Foos G, Hauser CA, Pasquale EB: The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol. 2006, 8 (8): 815-825. 10.1038/ncb1438.CrossRefPubMed
38.
Chiu ST, Chang KJ, Ting CH, Shen HC, Li H, Hsieh FJ: Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells. Carcinogenesis. 2009, 30 (9): 1475-1486. 10.1093/carcin/bgp133.CrossRefPubMed
39.
Kwiatkowski DJ: Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cardiol. 1999, 11 (1): 103-108.
40.
Khurana S, George SP: Regulation of cell structure and function by actin-binding proteins: villin's perspective. FEBS Lett. 2008, 582 (14): 2128-2139. 10.1016/j.febslet.2008.02.040.CrossRefPubMedPubMedCentral
41.
Zunino R, Li Q, Rose SD, Romero-Benitez MM, Lejen T, Brandan NC, Trifaro JM: Expression of scinderin in megakaryoblastic leukemia cells induces differentiation, maturation, and apoptosis with release of plateletlike particles and inhibits proliferation and tumorigenesis. Blood. 2001, 98 (7): 2210-2219. 10.1182/blood.V98.7.2210.CrossRefPubMed
42.
Miura N, Takemori N, Kikugawa T, Tanji N, Higashiyama S, Yokoyama M: Adseverin: a novel cisplatin-resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis. Mol Oncol. 2012, 6 (3): 311-322. 10.1016/j.molonc.2011.12.002.CrossRefPubMed
43.
Abouzahr-Rifai S, Hasmim M, Boukerche H, Hamelin J, Janji B, Jalil A, Kieda C, Mami-Chouaib F, Bertoglio J, Chouaib S: Resistance of tumor cells to cytolytic T lymphocytes involves Rho-GTPases and focal adhesion kinase activation. J Biol Chem. 2008, 283 (46): 31665-31672. 10.1074/jbc.M800078200.CrossRefPubMed
44.
Le QT, Kong C, Lavori PW, O'Byrne K, Erler JT, Huang X, Chen Y, Cao H, Tibshirani R, Denko N, et al: Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2007, 69 (1): 167-175. 10.1016/j.ijrobp.2007.01.071.CrossRefPubMed
45.
Tartour E, Deneux L, Mosseri V, Jaulerry C, Brunin F, Point D, Validire P, Dubray B, Fridman WH, Rodriguez J: Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study. Cancer. 1997, 79 (7): 1401-1408. 10.1002/(SICI)1097-0142(19970401)79:7<1401::AID-CNCR18>3.0.CO;2-3.CrossRefPubMed
46.
Wansom D, Light E, Thomas D, Worden F, Prince M, Urba S, Chepeha D, Kumar B, Cordell K, Eisbruch A, et al: Infiltrating lymphocytes and human papillomavirus-16–associated oropharyngeal cancer. Laryngoscope. 2012, 122 (1): 121-127. 10.1002/lary.22133.CrossRefPubMedPubMedCentral
47.
Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G: Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer. 2009, 9: 292-10.1186/1471-2407-9-292.CrossRefPubMedPubMedCentral
48.
Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA: Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J. 2007, 86 (8): 506-511.PubMed
49.
Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA: Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res. 2000, 6 (7): 2794-2802.PubMed
50.
Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S: HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006, 66 (18): 9281-9289. 10.1158/0008-5472.CAN-06-0488.CrossRefPubMed
51.
Nasman A, Andersson E, Nordfors C, Grun N, Johansson H, Munck-Wikland E, Massucci G, Dalianis T, Ramqvist T: MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome. Int J Cancer J Int Cancer. 2013, 132 (1): 72-81. 10.1002/ijc.27635.CrossRef
52.
Jung AC, Guihard S, Krugell S, Ledrappier S, Brochot A, Dalstein V, Job S, de Reynies A, Noel G, Wasylyk B, et al: CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. Int J Cancer J Int Cancer. 2013, 132 (2): E26-36. 10.1002/ijc.27776.CrossRef
53.
Distel LV, Fickenscher R, Dietel K, Hung A, Iro H, Zenk J, Nkenke E, Buttner M, Niedobitek G, Grabenbauer GG: Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol. 2009, 45 (10): e167-174. 10.1016/j.oraloncology.2009.05.640.CrossRefPubMed
54.
Nasman A, Romanitan M, Nordfors C, Grun N, Johansson H, Hammarstedt L, Marklund L, Munck-Wikland E, Dalianis T, Ramqvist T: Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PloS one. 2012, 7 (6): e38711-10.1371/journal.pone.0038711.CrossRefPubMedPubMedCentral
55.
Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N, Van Ryswick C, Quintin-Colonna F, Bruneval P, Brasnu D, et al: Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck. 2010, 32 (7): 946-958.PubMed
56.
Watanabe Y, Katou F, Ohtani H, Nakayama T, Yoshie O, Hashimoto K: Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol. 2010, 109 (5): 744-752. 10.1016/j.tripleo.2009.12.015.CrossRef
57.
Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, et al: A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood. 2011, 118 (18): 4853-4862. 10.1182/blood-2011-01-329656.CrossRefPubMed
Metadata
Title
Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+T cells
Authors
Meriem Hasmim
Cécile Badoual
Philippe Vielh
Françoise Drusch
Virginie Marty
Agnès Laplanche
Mariana de Oliveira Diniz
Hélène Roussel
Eléonore De Guillebon
Stéphane Oudard
Stéphane Hans
Eric Tartour
Salem Chouaib
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-592

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer

Research article

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis

Research article

Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study

Research article

Selenized milk casein in the diet of BALB/c nude mice reduces growth of intramammary MCF-7 tumors

Research article

Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma

Research article

Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits